TRAIL及其受体在乳腺癌中的研究进展

Progress of TRAIL and its receptors in breast cancer

肿瘤坏死因子相关调亡诱导配体（TRAIL）作为肿瘤坏死因子（TNF）家族的成员之一，可以选择性地诱导肿瘤细胞凋亡，对正常组织无明显毒副作用。基础研究发现多数乳腺癌细胞对TRAIL存在不同程度的耐药。但TRAIL与化疗、放疗、内分泌治疗、靶向治疗等联合应用常可见明显的协同作用。机制尚不明确，多数报道认为与诱导后DR4和（或）DR5的上调有关，明确的机制有待进一步研究。

TNF- related apoptosis- inducing ligand （TRAIL） is a member of the TNF gene superfarnily, which induces apoptosis selectively in many transformed eels but not in normal eels. Though some breast cancer cell lines are resistant to TRAIL,a synergetic effect can be seen when TRAIL is combined with some conventional therapies. The mechanism may be related to the up-regulation of DR4,DR5. and needs further studies.